User profiles for Jacqueline S. Garcia
Jacqueline Suen GarciaDana-Farber Cancer Institute Verified email at dfci.harvard.edu Cited by 4121 |
[HTML][HTML] Azacitidine and venetoclax in previously untreated acute myeloid leukemia
…, V Pullarkat, MJ Thirman, JS Garcia… - … England Journal of …, 2020 - Mass Medical Soc
Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis,
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …
[PDF][PDF] The public repository of xenografts enables discovery and randomized phase II-like trials in mice
…, AS Freedman, IA Galinsky, H Gao, JS Garcia… - Cancer cell, 2016 - cell.com
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient
efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX…
efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX…
[HTML][HTML] Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine
…, AC Schuh, MJ Thirman, JS Garcia… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE There is limited evidence on the clinical utility of monitoring measurable residual
disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. …
disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. …
[PDF][PDF] Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
…, ES Winer, MR Luskin, RM Stone, JS Garcia… - Cell stem cell, 2021 - cell.com
Some cancers originate from a single mutation event in a single cell. Blood cancers known
as myeloproliferative neoplasms (MPNs) are thought to originate when a driver mutation is …
as myeloproliferative neoplasms (MPNs) are thought to originate when a driver mutation is …
[HTML][HTML] Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy
CN Harrison, JS Garcia, TCP Somervaille… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Targeting the BCL-X L pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
…, F Efficace, G Garcia-Manero, JS Garcia… - Blood, The Journal …, 2023 - ashpublications.org
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …
clinical presentations and outcomes. The initial response criteria developed by the …
[PDF][PDF] Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia
…, E Halilovic, CP Paweletz, DM Weinstock, JS Garcia… - Cancer cell, 2020 - cell.com
Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important
clinical problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) …
clinical problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) …
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve
patients with FLT3-mutant acute myeloid leukemia. Patients and Methods: Data were pooled …
patients with FLT3-mutant acute myeloid leukemia. Patients and Methods: Data were pooled …
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have
a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. …
a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. …
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
This phase 1b trial ( NCT02670044 ) evaluated venetoclax-idasanutlin in patients with
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic chemotherapy. Two…
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic chemotherapy. Two…